Complexity in Early Phase Clinical Trials with Dr. Oren Cohen

<p><span style="font-weight: 400;">When a new drug or device undergoes “first in human” experience, the primary focus is on participant safety.</span> <span style="font-weight: 400;">How will the drug or device interact with the human body? </span><span style="font-weight: 400;">And will this interaction be safe?</span></p> <p><span style="font-weight: 400;">To answer these two questions, regulatory authorities around the world require medical product manufacturers to conduct Phase I, also known as early phase clinical trials.</span></p> <p><span style="font-weight: 400;">To learn more about the complexities in early phase clinical trials, I invited Dr. Oren Cohen, President of Clinical Pharmacology Services and Chief Medical Officer at Labcorp Drug Development on the show.</span></p> <p><span style="font-weight: 400;">Dr. Cohen has more than 30 years of healthcare experience which includes his work on clinical development. </span></p> <p><span style="font-weight: 400;">I hope you enjoy this conversation with Dr. Oren Cohen.</span></p> <p><strong>Podcast Sponsor:</strong></p> <p><span style="font-weight: 400;">This podcast episode is brought to you by Calyx.</span> <span style="font-weight: 400;">Calyx is a trusted name in medical imaging, having delivered imaging services to meet the needs of global biopharmaceutical sponsors and clinical research organizations for over 25 years. To learn more, visit <a href="https://calyx.ai" target="_blank" rel= "noopener">calyx.ai </a></span></p> <p> </p>